- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
FDA Green Lights Fast Track Designation to Tamibarotene for Higher-Risk MDS
January 27, 2023
Tamibarotene has received fast track designation from the FDA for use in patients with higher-risk myelodysplastic syndrome. The agent is being further evaluated in the phase 3 SELECT MDS-1 trial.
Myelofibrosis Types and Presentations
January 23, 2023
Stephen Oh, MD, PhD, explains the different types of myelofibrosis and describes the signs and symptoms.
Evaluating MRD Testing in the Real-World Setting for Patients Multiple Myeloma
January 20, 2023
Gayathri Ravi, MD, discusses the role of minimal residual disease testing in patients with newly diagnosed multiple myeloma.
Circulating Tumor DNA Measurement in Lymphoma One of the Big Stories From ASH
January 16, 2023
John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Hematology Workforce Shortage Poses Challenges for Cancer Care
January 09, 2023
Srikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.
Review of Myelodysplastic Syndromes Aids Experts in Diagnosing and Treating Patients
December 27, 2022
In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.
Coming Soon: Evaluating XPO1 Inhibitors in Multiple Myeloma and their Potential Role in Myelofibrosis
December 22, 2022
Expert hematologist-oncologists share insight on the evolving role of XPO1 inhibitor therapy in the management of multiple myeloma and myelofibrosis.
Safah Explores Disease Features and Treatment Options for Chronic GVHD
December 20, 2022
During a Targeted Oncology case-based roundtable event, Hana Safah, MD, discussed chronic graft-vs-host disease in terms of diagnosis, phases, risk assessment, and treatment options.
Treating Elderly Patients With ALL Remains a Challenge for Oncologists
December 16, 2022
In an interview with Targeted Oncology, Marlise Luskin, MD, MSCE, discussed the challenges of treating adult and elderly patients with acute lymphoblastic leukemia and where new research in the space is headed.
Impact of CAR T-Cell Therapy on Use of SCT for Hematologic Malignancies
December 13, 2022
Robert J. Soiffer, MD, discusses the approaches to integrating chimeric antigen receptor T-cell therapy into the treatment of hematologic malignancies.